BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29757324)

  • 1. Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients.
    Baeksted C; Pappot H; Nissen A; Hjollund NH; Mitchell SA; Basch E; Bidstrup PE; Dalton SO; Johansen C
    J Patient Rep Outcomes; 2017; 1(1):1. PubMed ID: 29757324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
    Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
    JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
    JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.
    Sandler KA; Mitchell SA; Basch E; Raldow AC; Steinberg ML; Sharif J; Cook RR; Kupelian PA; McCloskey SA
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):44-52. PubMed ID: 30102201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Pappot H; Baeksted C; Knoop A; Mitchell SA; Nissen A; Johansen C
    Breast J; 2019 Mar; 25(2):269-272. PubMed ID: 30761667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
    Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
    J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
    Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
    Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
    J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Wang TQ; Samuel JN; Brown MC; Vennettilli A; Solomon H; Eng L; Liang M; Gill G; Merali Z; Tian C; Cheng NYH; Campbell M; Patel D; Liu AX; Liu G; Howell D
    Oncol Ther; 2018 Dec; 6(2):189-201. PubMed ID: 32700029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.
    Albaba H; Barnes TA; Veitch Z; Brown MC; Shakik S; Su S; Naik H; Wang T; Liang M; Perez-Cosio A; Eng L; Mittmann N; Xu W; Howell D; Liu G
    Oncologist; 2019 Nov; 24(11):e1219-e1227. PubMed ID: 31409744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bennett AV; Dueck AC; Mitchell SA; Mendoza TR; Reeve BB; Atkinson TM; Castro KM; Denicoff A; Rogak LJ; Harness JK; Bearden JD; Bryant D; Siegel RD; Schrag D; Basch E;
    Health Qual Life Outcomes; 2016 Feb; 14():24. PubMed ID: 26892667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.
    Basch E; Dueck AC; Rogak LJ; Mitchell SA; Minasian LM; Denicoff AM; Wind JK; Shaw MC; Heon N; Shi Q; Ginos B; Nelson GD; Meyers JP; Chang GJ; Mamon HJ; Weiser MR; Kolevska T; Reeve BB; Bruner DW; Schrag D
    J Clin Oncol; 2018 Sep; 36(31):JCO2018788620. PubMed ID: 30204536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient reported outcomes interfering with daily activities in prostate cancer patients receiving antineoplastic treatment.
    Stormoen DR; Baeksted C; Taarnhøj GA; Johansen C; Pappot H
    Acta Oncol; 2021 Apr; 60(4):419-425. PubMed ID: 33641578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™).
    Veldhuijzen E; Walraven I; Mitchell SA; Moore EY; McKown SM; Lauritzen M; Kim KJ; Belderbos JSA; Aaronson NK
    J Patient Rep Outcomes; 2020 Oct; 4(1):81. PubMed ID: 33025309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.
    Speck RM; Lenderking WR; Shaw JW
    J Patient Rep Outcomes; 2017; 2():35. PubMed ID: 30175317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
    McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
    Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients' and Clinicians' Experiences.
    Tolstrup LK; Pappot H; Bastholt L; Zwisler AD; Dieperink KB
    J Med Internet Res; 2020 Apr; 22(4):e14896. PubMed ID: 32271150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events.
    Kawaguchi T; Azuma K; Sano M; Kim S; Kawahara Y; Sano Y; Shimodaira T; Ishibashi K; Miyaji T; Basch E; Yamaguchi T
    J Patient Rep Outcomes; 2017; 2(1):2. PubMed ID: 29757309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.